CS
CHRS icon

Candriam SCA’s Coherus Oncology CHRS Stock Holding History

Candriam SCA’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-680,812
Closed -$11.4M – 905
2021
Q1 		$11.4M Sell
680,812
-45
-0% -$764 0.09% 232
2020
Q4 		$11.8M Sell
680,857
-27,193
-4% -$484K 0.09% 236
2020
Q3 		$13M Buy
708,050
+41,678
+6% +$775K 0.12% 185
2020
Q2 		$11.9M Buy
666,372
+328,577
+97% +$5.56M 0.13% 189
2020
Q1 		$5.95M Buy
337,795
+74
+0% +$1.37K 0.07% 305
2019
Q4 		$6.08M Buy
337,721
+165,802
+96% +$3.06M 0.07% 311
2019
Q3 		$3.48M Buy
171,919
+106,919
+164% +$2.14M 0.05% 394
2019
Q2 		$1.43M Buy
+65,000
New +$1.13M 0.02% 587
2018
Q2 		– Sell
-85,000
Closed -$939K – 798
2018
Q1 		$939K Sell
85,000
-56,000
-40% -$613K 0.02% 609
2017
Q4 		$1.24M Sell
141,000
-52,000
-27% -$557K 0.02% 553
2017
Q3 		$2.58M Hold
193,000
– – 0.05% 403
2017
Q2 		$2.77M Sell
193,000
-95,000
-33% -$1.83M 0.05% 395
2017
Q1 		$6.09M Buy
288,000
+22,000
+8% +$541K 0.12% 211
2016
Q4 		$7.49M Buy
266,000
+75,000
+39% +$2.1M 0.17% 152
2016
Q3 		$5.12M Buy
+191,000
New +$5.21M 0.12% 189
2015
Q3 		– Sell
-40,000
Closed -$1.16M – 625
2015
Q2 		$1.16M Hold
40,000
– – 0.02% 427
2015
Q1 		$1.22M Buy
+40,000
New +$1.03M 0.02% 434

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Candriam SCA's CHRS Position: Q2 2021 in Review

Candriam SCA sold out of Coherus Oncology (CHRS) in Q2 2021, closing a stake of 680,812 shares — an estimated $11.4M sold.

Candriam SCA first reported a position in CHRS in Q1 2015 and held it in 17 quarters. The position peaked at $13M in Q3 2020. 188 funds tracked by Wall St. Rank hold CHRS as of Q2 2021.

  • Candriam SCA reported no remaining Coherus Oncology position as of Q2 2021 after selling out during the quarter.
  • Candriam SCA sold 680,812 Coherus Oncology shares in Q2 2021, an estimated $11.4M.
  • Candriam SCA first reported a position in Coherus Oncology in Q1 2015 and held it in 17 quarters.
  • Candriam SCA's Coherus Oncology position peaked at $13M in Q3 2020.
  • 188 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2021.

Based on Candriam SCA's 13F filing for Q2 2021, filed 20 Jul 2021.